First Time Loading...

Indaptus Therapeutics Inc
NASDAQ:INDP

Watchlist Manager
Indaptus Therapeutics Inc Logo
Indaptus Therapeutics Inc
NASDAQ:INDP
Watchlist
Price: 2.18 USD -7.23% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

INDP doesn't have a meaningful market cap.
INDP's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]

The intrinsic value of one INDP stock under the Base Case scenario is 1.56 USD. Compared to the current market price of 2.18 USD, Indaptus Therapeutics Inc is Overvalued by 28%.

Key Points:
INDP Intrinsic Value
Base Case
1.56 USD
Overvaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Indaptus Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling INDP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Indaptus Therapeutics Inc

Provide an overview of the primary business activities
of Indaptus Therapeutics Inc.

What unique competitive advantages
does Indaptus Therapeutics Inc hold over its rivals?

What risks and challenges
does Indaptus Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Indaptus Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Indaptus Therapeutics Inc.

Provide P/S
for Indaptus Therapeutics Inc.

Provide P/E
for Indaptus Therapeutics Inc.

Provide P/OCF
for Indaptus Therapeutics Inc.

Provide P/FCFE
for Indaptus Therapeutics Inc.

Provide P/B
for Indaptus Therapeutics Inc.

Provide EV/S
for Indaptus Therapeutics Inc.

Provide EV/GP
for Indaptus Therapeutics Inc.

Provide EV/EBITDA
for Indaptus Therapeutics Inc.

Provide EV/EBIT
for Indaptus Therapeutics Inc.

Provide EV/OCF
for Indaptus Therapeutics Inc.

Provide EV/FCFF
for Indaptus Therapeutics Inc.

Provide EV/IC
for Indaptus Therapeutics Inc.

Show me price targets
for Indaptus Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Indaptus Therapeutics Inc?

How accurate were the past Revenue estimates
for Indaptus Therapeutics Inc?

What are the Net Income projections
for Indaptus Therapeutics Inc?

How accurate were the past Net Income estimates
for Indaptus Therapeutics Inc?

What are the EPS projections
for Indaptus Therapeutics Inc?

How accurate were the past EPS estimates
for Indaptus Therapeutics Inc?

What are the EBIT projections
for Indaptus Therapeutics Inc?

How accurate were the past EBIT estimates
for Indaptus Therapeutics Inc?

Compare the revenue forecasts
for Indaptus Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Indaptus Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Indaptus Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Indaptus Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Indaptus Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Indaptus Therapeutics Inc with its peers.

Analyze the financial leverage
of Indaptus Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Indaptus Therapeutics Inc.

Provide ROE
for Indaptus Therapeutics Inc.

Provide ROA
for Indaptus Therapeutics Inc.

Provide ROIC
for Indaptus Therapeutics Inc.

Provide ROCE
for Indaptus Therapeutics Inc.

Provide Gross Margin
for Indaptus Therapeutics Inc.

Provide Operating Margin
for Indaptus Therapeutics Inc.

Provide Net Margin
for Indaptus Therapeutics Inc.

Provide FCF Margin
for Indaptus Therapeutics Inc.

Show all solvency ratios
for Indaptus Therapeutics Inc.

Provide D/E Ratio
for Indaptus Therapeutics Inc.

Provide D/A Ratio
for Indaptus Therapeutics Inc.

Provide Interest Coverage Ratio
for Indaptus Therapeutics Inc.

Provide Altman Z-Score Ratio
for Indaptus Therapeutics Inc.

Provide Quick Ratio
for Indaptus Therapeutics Inc.

Provide Current Ratio
for Indaptus Therapeutics Inc.

Provide Cash Ratio
for Indaptus Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Indaptus Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Indaptus Therapeutics Inc?

What is the current Free Cash Flow
of Indaptus Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Indaptus Therapeutics Inc.

Financials

Balance Sheet Decomposition
Indaptus Therapeutics Inc

Current Assets 14m
Cash & Short-Term Investments 13.4m
Other Current Assets 633.2k
Non-Current Assets 928.7k
PP&E 173.9k
Other Non-Current Assets 754.7k
Current Liabilities 2.8m
Accounts Payable 806k
Accrued Liabilities 2m
Non-Current Liabilities 73.4k
Other Non-Current Liabilities 73.4k
Efficiency

Earnings Waterfall
Indaptus Therapeutics Inc

Revenue
0 USD
Operating Expenses
-16.4m USD
Operating Income
-16.4m USD
Other Expenses
955k USD
Net Income
-15.4m USD

Free Cash Flow Analysis
Indaptus Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

INDP Profitability Score
Profitability Due Diligence

Indaptus Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

36/100
Profitability
Score

Indaptus Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

INDP Solvency Score
Solvency Due Diligence

Indaptus Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Indaptus Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INDP Price Targets Summary
Indaptus Therapeutics Inc

Wall Street analysts forecast INDP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INDP is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 12.6 USD.

Lowest
Price Target
8.08 USD
271% Upside
Average
Price Target
10.2 USD
368% Upside
Highest
Price Target
12.6 USD
478% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

INDP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

INDP Price
Indaptus Therapeutics Inc

1M 1M
-22%
6M 6M
+2%
1Y 1Y
-15%
3Y 3Y
-88%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
2.18
52w Low
1.6
52w High
3.95
Price Metrics
Average Annual Return -71.9%
Standard Deviation of Annual Returns 15.2%
Max Drawdown -100%
Shares Statistics
Market Capitalization 18.3m USD
Shares Outstanding 8 538 880
Percentage of Shares Shorted 1.67%

INDP Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Indaptus Therapeutics Inc Logo
Indaptus Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

18.3m USD

Dividend Yield

0%

Description

Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Contact

NEW YORK
JERUSALEM
12 Hartom Street (RMPE building), P.O.Box 45219
+97225869176.0
https://www.intecpharma.com

IPO

2012-09-07

Employees

-

Officers

CEO & Director
Mr. Jeffrey A. Meckler
Chief Operating Officer
Mr. Walt Addison Linscott Esq.
Founder, Chief Scientific Officer & Director
Dr. Michael J. Newman Ph.D.
CFO, Secretary & Treasurer
Mr. Nir Sassi
Chief Medical Officer
Dr. Roger J. Waltzman M.B.A., M.D.

See Also

Discover More
What is the Intrinsic Value of one INDP stock?

The intrinsic value of one INDP stock under the Base Case scenario is 1.56 USD.

Is INDP stock undervalued or overvalued?

Compared to the current market price of 2.18 USD, Indaptus Therapeutics Inc is Overvalued by 28%.